相关实验视频
Updated: Jan 10, 2026

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.3K
在心脏毒性癌症治疗期间,可溶性抑制瘤发生性-2 变化:系统性审查和元分析
Luca Fazzini1, Simone Angius1, Nicola Campana1
1Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Frontiers in cardiovascular medicine
|November 27, 2025
概括
溶性抑制瘤发生性-2 (sST2) 水平在癌症治疗期间发生变化,与心脏毒性相关. 虽然热素显示出更大的纵向变化,但sST2提供了有关癌症治疗期间心脏损伤的见解.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 生物标志物研究 生物标志物研究
背景情况:
- 瘤发生性-2 (sST2) 的可溶性抑制被认为是心血管疾病和心力衰竭的生物标志物.
- 关于癌症治疗期间sST2度变化及其与心脏毒性相关的数据有限.
研究的目的:
- 在心脏毒性癌症治疗期间系统地审查和元分析sST2水平的纵向变化.
- 为了比较sST2的动态与传统的心脏损伤生物标志物,如素和NT-proBNP.
- 评估sST2水平与心脏毒性之间的相关性,以左心室喷射率 (LVEF) 定义.
主要方法:
- 对8项涉及433名接受 antracycline 和/或 HER2 定向治疗的患者的研究进行了系统审查和元分析.
- 在基线 (T0),化疗后 (T1) 和随访 (T2) 的sST2水平分析.
- 利用随机效应模型计算生物标志物变异和相关性的平均差异 (MD) 和标准化平均差异 (SMD).
主要成果:
- 观察到从T0到T2增加sST2 (MD 1.86) 和从T1到T2 (MD -1.96) 降低水平的趋势,尽管在统计学上并不显著.
- 在sST2水平和LVEF之间发现了显著的负相关性 (r -0.29,p < 0.010),表明高的sST2与心脏功能降低.
- 与sST2.2.相比,托波从T0到T1的纵向变化 (SMD) 显著增加.
结论:
- sST2在心脏毒性癌症治疗期间表现出动态变化,与心脏毒性相关.
- 与sST2.2相比,托罗邦尼显示出更明显的纵向变化.
- 需要进一步的研究来调查患有心脏毒性的人与不患心脏毒性的人的纵向sST2水平.
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Loss of Tumor Suppressor Gene Functions
5.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.8K
Mutagenicity and Carcinogenicity
1.8K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

